

First Name	Family Name	Presentation No	Submission No.	Session	Type	Title	Country	Day	Place	Start Time	End Time	Min.
Passakorn	Wanchaijiraboon	FPS1-1	10053	Free Paper Session 1	Oral	Implementing Community-Based Hepatitis B Screening and Hepatocellular Carcinoma Screening in Resource-Limited Settings: A Qualitative Evaluation of Thailand's EZ Liver Network	Thailand	April 2 (Day 1)	Room 2	9:10	9:18	8min.
Mohamed	Abdel-Samiee	FPS1-2	10223	Free Paper Session 1	Oral	A Large-Center Comparison of Hepatocellular Carcinoma Characteristics in Hepatitis C Patients Treated With Direct-Acting Antivirals Versus Untreated Patients	Egypt	April 2 (Day 1)	Room 2	9:18	9:26	8min.
Yuji	Ikeda	FPS1-3	10107	Free Paper Session 1	Oral	Reduced Performance of Alpha-fetoprotein in Sustained Virological Response-related and Non-viral Early Hepatocellular Carcinoma: Complementary Value of PIVKA-II	Japan	April 2 (Day 1)	Room 2	9:26	9:34	8min.
Katsuya	Nagaoka	FPS1-4	10131	Free Paper Session 1	Oral	Clinical Characteristics and Surveillance Impact on Non-Viral Hepatocellular Carcinoma: A 20-Year Observational Study	Japan	April 2 (Day 1)	Room 2	9:34	9:42	8min.
Hiroyuki	Suzuki	FPS1-5	10118	Free Paper Session 1	Oral	Integrative Clinical and Molecular Risk Score for Prevention of HBV-related HCC	USA	April 2 (Day 1)	Room 2	9:42	9:50	8min.
Hiroaki	Kanzaki	FPS1-6	10120	Free Paper Session 1	Oral	Serum Biomarker-based Score to Evaluate HCC Risk in HCV-cured Patients	USA	April 2 (Day 1)	Room 2	9:50	9:58	8min.
Yin Min	Hwang	FPS2-1	10123	Free Paper Session 2	Oral	Hepatocellular Carcinoma Stage, Treatment Patterns, and Survival Outcomes in a Contemporary Multicentre International Cohort	Singapore	April 2 (Day 1)	Room 2	10:00	10:08	8min.
Juequn	Zhou	FPS2-2	10091	Free Paper Session 2	Oral	Development and Validation of a Deep Learning Model to Prognosticate Hepatocellular Carcinoma	Singapore	April 2 (Day 1)	Room 2	10:08	10:16	8min.
Amruthavarshini	Nagabhushana	FPS2-3	10122	Free Paper Session 2	Oral	Young Onset Hepatocellular Carcinoma Presents at Advanced Stage with Limited Treatment Options	India	April 2 (Day 1)	Room 2	10:16	10:24	8min.
Ankush	Kumar	FPS2-4	10136	Free Paper Session 2	Oral	Environmental Exposure to Cadmium, Lead, and Mercury as a Public Health Risk Factor for Hepatocellular Carcinoma	India	April 2 (Day 1)	Room 2	10:24	10:32	8min.
Takumi	Kawaguchi	FPS2-5	10151	Free Paper Session 2	Oral	Feasibility and Safety of Hepatic Rehabilitation in HCC Patients with Decompensated Cirrhosis	Japan	April 2 (Day 1)	Room 2	10:32	10:40	8min.
Lei	Kong	FPS3-1	10011	Free Paper Session 3	Oral	Aging-Driven Immunosuppressive Remodeling of the Tumor Microenvironment in Gallbladder Cancer: Insights from Single-Cell Transcriptomics	China	April 2 (Day 1)	Room 2	11:00	11:08	8min.
Xing	Yu	FPS3-2	10144	Free Paper Session 3	Oral	KLF5 Mediates a Galectin1-FBP1-RAS/ERK Cascade to Drive Proliferation and Migration in Intrahepatic Cholangiocarcinoma	China	April 2 (Day 1)	Room 2	11:08	11:16	8min.
Yuheng	Hu	FPS3-3	10167	Free Paper Session 3	Oral	Lactylation of PPP1CA at K305 Promotes Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma by Sustaining TGF- $\beta$ Signaling	China	April 2 (Day 1)	Room 2	11:16	11:24	8min.
Asgar	Ali	FPS3-4	10202	Free Paper Session 3	Oral	Epigenetic Silencing of PTEN as a Prognostic and Translational Biomarker in Periampullary Adenocarcinoma	India	April 2 (Day 1)	Room 2	11:24	11:32	8min.
Tsuyoshi	Takeda	FPS3-5	10184	Free Paper Session 3	Oral	Prognostic impact of adipose tissue volume in unresectable biliary tract cancer treated with gemcitabine, cisplatin, and immunotherapy	Japan	April 2 (Day 1)	Room 2	11:32	11:40	8min.
Keito	Nakagawa	FPS3-6	10172	Free Paper Session 3	Oral	Feasibility and Safety of Endoscopic Ultrasound-guided Tissue Acquisition for Biliary Lesions	Japan	April 2 (Day 1)	Room 2	11:40	11:48	8min.
Wenjing	Yuan	LBS1-1	10248	Late Breaker Session 1	Oral	HLA-DR<sup>+</sup></sup> Tumor Cells Mimic Antigen-presenting Cells to Mediate Immunosuppression in HBV-related Hepatocellular Carcinoma	China	April 2 (Day 1)	Room 2	13:30	13:38	8min.
Jinhui	Wei	LBS1-2	10236	Late Breaker Session 1	Oral	High Ammonia Promotes EHHADH-dependent Pyrimidine Degradation to Induce Inflammatory Cell Death in HCC	China	April 2 (Day 1)	Room 2	13:38	13:46	8min.
Ryo	Morise	LBS1-3	10239	Late Breaker Session 1	Oral	Sarcomatoid Transformation is Associated with Immunosuppressive Remodeling in Hepatocellular Carcinoma	Japan	April 2 (Day 1)	Room 2	13:46	13:54	8min.
Hiroshi	Ohyama	LBS1-4	10254	Late Breaker Session 1	Oral	Bile-based Liquid Biopsy for Diagnosis and Therapeutic Stratification of Biliary Strictures	Japan	April 2 (Day 1)	Room 2	13:54	14:02	8min.
Amith	Vishwanath	LBS2-1	10246	Late Breaker Session 2	Oral	Large Language Models Underperform Multidisciplinary Teams for Hepatocellular Carcinoma Treatment Decisions Despite Escalating Prompting Strategies: A Prospective Study	India	April 2 (Day 1)	Room 2	14:02	14:10	8min.
Jun-Hao	Mei	LBS2-2	10272	Late Breaker Session 2	Oral	Causal Machine Learning-Guided Personalized Immunochemotherapy Strategies in Intrahepatic Cholangiocarcinoma	China	April 2 (Day 1)	Room 2	14:10	14:18	8min.
Jianhua	Rao	LBS2-3	10232	Late Breaker Session 2	Oral	NEO-ERA-01: A phase II Study of Neoadjuvant HAIC (GEMOX) Plus Adebrelimab and Lenvatinib in High-risk Resectable Intrahepatic Cholangiocarcinoma	China	April 2 (Day 1)	Room 2	14:18	14:26	8min.
Shuntaro	Obi	LBS2-4	10250	Late Breaker Session 2	Oral	Stage-dependent Liver Stiffness Resolution after HCV SVR: a Longitudinal 8-year Follow-up Study	Japan	April 2 (Day 1)	Room 2	14:26	14:34	8min.
Jianhua	Rao	LBS3-1	10241	Late Breaker Session 3	Oral	Efficacy and Safety of Postoperative Adjuvant Donafenib Therapy in Patients with High-risk Recurrence after Radical Resection of Hepatocellular Carcinoma: A Multicenter Retrospective Study	China	April 2 (Day 1)	Room 2	14:50	14:58	8min.
Yuki	Matsushita	LBS3-2	10273	Late Breaker Session 3	Oral	The Risk of Decompensation in Steatotic Liver Disease-related Hepatocellular Carcinoma after Curative Treatment	Japan	April 2 (Day 1)	Room 2	14:58	15:06	8min.
Chaiyaboot	Ariyachet	FPS4-1	10094	Free Paper Session 4	Oral	MicroRNA-199a-5p Disrupts Unfolded Protein Response-mediated Stress Adaptation in Hepatocellular Carcinoma Cells	Thailand	April 2 (Day 1)	Room 2	15:10	15:18	8min.
Boqiang	Liu	FPS4-2	10108	Free Paper Session 4	Oral	Dynamic Regulation of Membrane Fluidity Drives Tumor Evolution and Attenuates TNF $\alpha$ -Mediated Apoptosis in Hepatocellular Carcinoma	China	April 2 (Day 1)	Room 2	15:18	15:26	8min.
Yiming	Wang	FPS4-3	10162	Free Paper Session 4	Oral	AARS1 Promotes Tumor Progression and Immune Evasion through ATF6 Lactylation-driven Tryptophan Metabolism in Hepatocellular Carcinoma	China	April 2 (Day 1)	Room 2	15:26	15:34	8min.
Tomoya	Hamabe	FPS4-4	10178	Free Paper Session 4	Oral	Dfn5-dependent Hepatocyte Death Promotes Inflammatory TNF Signaling in Kupffer Cells to Drive Hepatocarcinogenesis	Japan	April 2 (Day 1)	Room 2	15:34	15:42	8min.
Liang	Shi	FPS5-1	10100	Free Paper Session 5	Oral	Natural Killer Cell Drives Liver Cancer Evolution Through Cholesterol Metabolism Reprogramming	China	April 2 (Day 1)	Room 2	15:45	15:53	8min.
Yuchan	Xue	FPS5-2	10147	Free Paper Session 5	Oral	A Fe-Curcumin-based Strategy to Reinvigorate CAR-T Cells by Reversing Exhaustion and Senescence in Liver Cancer	China	April 2 (Day 1)	Room 2	15:53	16:01	8min.
Hiroaki	Kanzaki	FPS5-3	10119	Free Paper Session 5	Oral	Reverse-engineering Strategy Identified DDR1 as HCC Chemoprevention Target Post HCV Cure	USA	April 2 (Day 1)	Room 2	16:01	16:09	8min.
Takeru	Hirao	PS-1	10177	Plenary Session	Oral	Plasma TWEAK as a Predictive Biomarker of Response to Tremelimumab plus Durvalumab in Advanced Hepatocellular Carcinoma	Japan	April 3 (Day 2)	Room 1	16:05	16:15	10min.
Norifumi	Iseda	PS-2	10130	Plenary Session	Oral	Surgical Benefit and Futility in Borderline Resectable Hepatocellular Carcinoma: A Multicenter Study	Japan	April 3 (Day 2)	Room 1	16:15	16:25	10min.
Xingru	Wang	PS-3	10003	Plenary Session	Oral	The First Application and Feasibility Assessment of 5G-enabled Remote Robot-assisted Hepatobiliary and Pancreatic Surgery in Patients with Malignant Tumors	China	April 3 (Day 2)	Room 1	16:25	16:35	10min.
Gakushi	Kitamura	VS-1	10073	Video Session	Video	Pitfalls in Posterior Sectionectomy and S7 Segmentectomy Focusing on the Running Pattern of the Right Posterior Inferior Portal Branch (P6a) and Portal Vein Branching Anatomy	Japan	April 3 (Day 2)	Room 2	9:00	9:12	12min.
Yusuke	Yamamoto	VS-2	10074	Video Session	Video	Surgical Strategy for Laparoscopic Right Intersectional Plane Resection in Right Anterior/Posterior Sectionectomy and S7/S8 Segmentectomy, Based on the Courses of P6a and the Right Hepatic Vein	Japan	April 3 (Day 2)	Room 2	9:12	9:24	12min.
Xingru	Wang	VS-3	10004	Video Session	Video	Infrared Laser-guided Laparoscopic Portal Vein Drainage Area Anatomic Liver Resection Using ICG Positive Staining	China	April 3 (Day 2)	Room 2	9:24	9:36	12min.
Rie	Shibata	VS-4	10077	Video Session	Video	Optimizing Specimen Extraction in Laparoscopic Resection of Giant Liver Tumors Using a Pfannenstiel Incision	Japan	April 3 (Day 2)	Room 2	9:36	9:48	12min.
Taisuke	Imamura	VS-5	10143	Video Session	Video	Advanced Minimally Invasive Hepatectomy Through Standardized Hepatic Vein Control- Translating Laparoscopic Strategies to Robotic Surgery -	Japan	April 3 (Day 2)	Room 2	9:48	10:00	12min.
Mei	Nakamura	VS-6	10069	Video Session	Video	Initial Experience with Robot-assisted Liver Resection Using the da Vinci SP System	Japan	April 3 (Day 2)	Room 2	10:00	10:12	12min.
Hiroki	Yamana	VS-7	10090	Video Session	Video	EUS-Guided Portal Vein Sampling as a Novel Liquid Biopsy Approach for Pancreatic Cancer	Japan	April 3 (Day 2)	Room 2	10:12	10:24	12min.
Chikako	Nagao	FPS6-1	10038	Free Paper Session 6	Oral	Clinical Characteristics of Combination Immunotherapy in Elderly Patients with Unresectable Hepatocellular Carcinoma	Japan	April 3 (Day 2)	Room 2	10:45	10:53	8min.
Tomonao	Taira	FPS6-2	10064	Free Paper Session 6	Oral	Prognostic Value of Combined Child&ndash; Pugh Score and Modified Albumin&ndash;Bilirubin Grade in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab	Japan	April 3 (Day 2)	Room 2	10:53	11:01	8min.
Yumi	Otoyama	FPS6-3	10106	Free Paper Session 6	Oral	Association of Lenvatinib Pharmacokinetics with mALBI in Hepatocellular Carcinoma and Evaluation of Efficacy and Safety	Japan	April 3 (Day 2)	Room 2	11:01	11:09	8min.
Qian	Chen	FPS6-4	10139	Free Paper Session 6	Oral	Regional Lymph Node Metastasis in Hepatocellular Carcinoma Treated with Immune-based Systemic Therapy: Prognostic Significance and Implications for Clinical Staging	China	April 3 (Day 2)	Room 2	11:09	11:17	8min.
Long-Wang	Lin	FPS7-1	10097	Free Paper Session 7	Oral	Should Transarterial Chemoembolization Be Applied with Systemic Therapy for Hepatocellular Carcinoma with Hepatic Vein and/or Inferior Vena Cava Tumor Thrombus?: A Multicenter Study	China	April 3 (Day 2)	Room 2	11:17	11:25	8min.
Soe Thiha	Maung	FPS7-2	10160	Free Paper Session 7	Oral	Real-World Outcomes of Sequential Transarterial Chemoembolization followed by Atezolizumab-Bevacizumab in Patients with Advanced Hepatocellular Carcinoma	Thailand	April 3 (Day 2)	Room 2	11:25	11:33	8min.
Joji	Tani	FPS7-3	10183	Free Paper Session 7	Oral	Efficacy of Combined Three-Dimensional Conformal Radiotherapy and Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with Major Vascular Invasion	Japan	April 3 (Day 2)	Room 2	11:33	11:41	8min.
Hayato	Abe	FPS8-1	10111	Free Paper Session 8	Oral	Prognostic Impact of the Oncological Resectability Criteria in Patients Undergoing Liver Resection for Hepatocellular Carcinoma	Japan	April 3 (Day 2)	Room 2	13:30	13:38	8min.
Atomu	Suzuki	FPS8-2	10078	Free Paper Session 8	Oral	Surgical Outcomes and Treatment Strategies for Solitary Giant Hepatocellular Carcinoma	Japan	April 3 (Day 2)	Room 2	13:38	13:46	8min.
Ting	Luo	FPS8-3	10146	Free Paper Session 8	Oral	Association between Prophylactic Antibiotics and Post-ablation Infections in Hepatocellular Carcinoma Patients: A Retrospective Multicenter Cohort Study	China	April 3 (Day 2)	Room 2	13:46	13:54	8min.
Chitchai	Rattananukrom	FPS9-1	10076	Free Paper Session 9	Oral	PIVKA-II Monitoring to Predict Response to the First Transarterial Chemoembolization (TACE) in Intermediate-Stage Hepatocellular Carcinoma	Thailand	April 3 (Day 2)	Room 2	13:55	14:03	8min.

First Name	Family Name	Presentation No	Submission No.	Session	Type	Title	Country	Day	Place	Start Time	End Time	Min.
Atteyat	Semeya	FPS9-2	10158	Free Paper Session 9	Oral	Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Refractory Gastrointestinal Bleeding in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis: A Prospective Cohort Study	Saudi Arabia	April 3 (Day 2)	Room 2	14:03	14:11	8min.
Masaya	Sato	FPS10-1	10029	Free Paper Session 10	Oral	Development of Novel Deep Multimodal Representation Learning-based Model for the Differentiation of Liver Tumors on B-Mode Ultrasound Images	Japan	April 3 (Day 2)	Room 2	14:15	14:23	8min.
Aldisa	Puspitasari	FPS10-2	10204	Free Paper Session 10	Oral	Dissociation Between Multiphasic CT-Defined Tumor Burden and Endoscopic Portal Hypertension Severity in Cirrhotic and Non-Cirrhotic Hepatocellular Carcinoma	Indonesia	April 3 (Day 2)	Room 2	14:23	14:31	8min.
Phool	Chand	FPS10-3	10210	Free Paper Session 10	Oral	Stereotactic Body Radiotherapy Enhances the Efficacy of Nivolumab in Advanced Hepatocellular Carcinoma: A Comparative Cohort Analysis	India	April 3 (Day 2)	Room 2	14:31	14:39	8min.
Vanilla Xin	Zhang	YIA1-1	10013	Young Investigator Award Session 1	Oral	Repurposing Resmetrom Suppresses MASH-associated Hepatocellular Carcinoma, with Mechanistic Implications of MDK/LRP1-mediated Metabolic Reprogramming and Immunosuppression	Hong Kong	April 3 (Day 2)	Room 2	15:00	15:08	8min.
Firdian	Makrufardi	YIA1-2	10017	Young Investigator Award Session 1	Oral	Transitional Hepatocytes and Immunosuppressive Macrophages Drive NASH-Associated Liver Cancer Revealed by Single-Cell Transcriptomics	Indonesia	April 3 (Day 2)	Room 2	15:08	15:16	8min.
Kenji	Nose	YIA1-3	10047	Young Investigator Award Session 1	Oral	Gemcitabine Modulates the Tumor Immune Microenvironment to Enhance Response to Immune-checkpoint Inhibitors in Biliary Tract Cancer	Japan	April 3 (Day 2)	Room 2	15:16	15:24	8min.
Masaki	Omori	YIA1-4	10065	Young Investigator Award Session 1	Oral	Strategic Integration of Locoregional Interventions to Optimize Survival Outcomes following First-line ICI Combinations in Advanced Hepatocellular Carcinoma	Japan	April 3 (Day 2)	Room 2	15:24	15:32	8min.
Takashi	Kitagataya	YIA2-1	10020	Young Investigator Award Session 2	Oral	Impact of Antihypertensive Drug Selection on Proteinuria Risk During Atezolizumab Plus Bevacizumab Therapy for Hepatocellular Carcinoma	Japan	April 3 (Day 2)	Room 2	15:32	15:40	8min.
Satoshi	Narahara	YIA2-2	10060	Young Investigator Award Session 2	Oral	Pretreatment Serum Heparin-Binding Protein as a Predictive Biomarker for Atezolizumab Plus Bevacizumab Therapy in Advanced Hepatocellular Carcinoma	Japan	April 3 (Day 2)	Room 2	15:40	15:48	8min.
Tomoaki	Hayakawa	YIA2-3	10041	Young Investigator Award Session 2	Oral	Novel Risk Score Incorporating Type-IV Collagen, Albumin, and Prothrombin Time (CAP score) to Predict 180-Day Surgery-Related Mortality After Liver Resection for Hepatocellular Carcinoma	Japan	April 3 (Day 2)	Room 2	15:48	15:56	8min.
Takuma	Kaneko	YIA2-4	10070	Young Investigator Award Session 2	Oral	Unexpected Rapid Progression of Hepatocellular Carcinoma After Radiofrequency Ablation	Japan	April 3 (Day 2)	Room 2	15:56	16:04	8min.